Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab every-4-week maintenance-style dosing after induction in relapsed/refractory cutaneous T-cell lymphoma
2020-004537-20Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Kyowa Kirin. Primary endpoint: Treatment-emergent adverse events. Started Jun 2021; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2020-004537-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004537-20.